Montelukast in the management of allergic rhinitis

Therapeutics and Clinical Risk Management

Volumn 3, Issue 2, 2007, Pages 327-332

  Lagos, Jaime A ^a   Marshall, Gailen D ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Allergic rhinitis; Drug therapy; Management; Montelukast

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BUDESONIDE; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DIGOXIN; FEXOFENADINE; FLUTICASONE; LEUKOTRIENE RECEPTOR; LORATADINE; MOMETASONE FUROATE; MONTELUKAST; PLACEBO; TERFENADINE; THEOPHYLLINE; WARFARIN;

AGE; ALLERGIC RHINITIS; ANAMNESIS; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENVIRONMENTAL EXPOSURE; HAY FEVER; HEALTH CARE COST; HEART PALPITATION; HUMAN; HYPERTENSION; MONOTHERAPY; OTITIS MEDIA; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PHARYNGITIS; PHYSICAL EXAMINATION; QT PROLONGATION; QUALITY OF LIFE; REVIEW; RHINITIS; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOCIOECONOMICS; TACHYPHYLAXIS; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

EID: 34249977552     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.2.327     Document Type: Review

References (43)

1. [AAAAI] American Academy of Allergy, Asthma, and Immunology. 2000. The allergy report [online]. Accessed 22 November 2005. URL: http://www.aaaai.org/ar/volume1.pdf.
2. Bernstein DI, Levy AL, Hampel FC, et al. 2004. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy, 34:952-7.
3. Bjornsdottir US, Jakobinudottir S, Runarsdottir V, et al. 2003. The effect of reducing levels of car allergen (Fel d 1) on clinical symptoms in patients with cat allergy. Ann Allergy Asthma Immunol, 91:189-94.
4. Bousquet J, Lund VJ, van Cauwenberge P, et al. 2003. Implementation of guidelines for seasonal allergic rhinits:a randomized controlled trial. Allergy, 58:733-41.
5. Bousquet J, van Cauwenberge P, Khaltaev N, et al. 2001. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol, 108:S147-334.
6. Corrado OJ, Gould CA, Kassab JY, et al. 1986. Nasal response of rhinitic and non-rhinitic subjects to histamine and methacholine: a comparative study. Thorax, 41:863-8.
7. Corren J, Adinoff AD, Irvin CG. 1992. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol, 90:250-6.
8. Corren J. 1997. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol, 99:S781-6.
9. Custovic A, van Wijk RG. 2005. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA2LEN). Allergy, 60:1112-15.
10. Dykewicz MS, Fineman S, Skoner DP, et al. 1998. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol, 81:478-518.
11. Gerth-van-Wijk R, Dieges PH. 1991. Nasal hyper-responsiveness to histamine, methacholine and phentolamine in patients with perennial nonallergic rhinitis and in patients with infectious rhinitis. Clin Otolaryngol, 16:133-7.
12. Gotzsche PC, Hammarquist C, Burr M. 1998. House dust mite control measures in the management of asthma: meta-analysis. BMJ, 317:1105-10; discussion, 1110.
13. Graf P, Hallen H, Juto JE. 1995. Four-week use of oxymetazoline nasal spray (Nezeril) once daily at night induces rebound swelling and nasal hyperreactivity. Acta Otolaryngol, 115:71-5.
14. Graf P, Hallen H. 1996. Effect on the nasal mucosa of long-term treatment with oxymetazoline, benzalkonium chloride, and placebo nasal sprays. Laryngoscope, 106:605-9.
15. Jordana G, Dolovich J, Briscoe MP, et al. 1996. Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis. J Allergy Clin Immunol, 97:588-95.
16. Kilburn S, Lasserson TJ, McKean M. 2001. Pet allergen control measures for allergic asthma in children and adults. Cochrane Database Syst Rev, 1:CD002989.
17. Kurowski M, Kuna P, Gorski P. 2004. Montelukast plus ceterizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy, 59:280-8.
18. Ledford DK, Lockey RF. 1998. Allergic rhinitis: Understanding the process (a major contributor to health problems-and on the rise). J Respir Dis, 19:576-84.
19. Malm L, Gerth-van-Wijk R, Bachert C. 1999. Guildelines for nasal provocations with aspects on nasal patency, airflow, and airflow resitance. Rhinology, 37:133-5.
20. Markham A, Faulds D. 1998. Montelukast. Drugs, 56:251-6.
21. Martin B, Andrews CP, van Bavel JH, et al. 2005. Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. Ann Allergy Asthma Immunol, 96:851-7.
22. McMenamin P. 1994. Costs of hay fever in the United States in 1990. Ann Allergy, 73:35-9.
23. Meltzer EO, Malmstrom K, Lu S, et al. 2000. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol, 105:917-22.
24. Nathan RA, Meltzer EO, Selner JC, et al. 1997. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol, 99:S808-S14.
25. Nayak AS, Philip G, Lu S, et al. 2002. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double blind, placebo controlled trial performed in the fall. Ann Allergy Asthma Immunol, 88:592-600.
26. Patel P, Philip G, Yang W, et al. 2005. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol, 95:551-7.
27. Perry TT, Corren J, Philip G, et al. 2004. Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure. Ann Allergy Asthma Immunol, 93:431-8.
28. Philip G, Malmstrom K, Hampel FC, et al. 2002. Montelukast for treating seasonal allergic rhinitis: a randomized, double blind, placebo-controlled trial performed in the spring. Clin Exp Allergy, 32:1020-8.
29. Philip G, Nayak A, Berger W, et al. 2004. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin, 10:1549-58.
30. Phipatanakul W, Nowak-Wegrzyn A, Eggleston PA, et al. 2002. The efficacy of montelukast in the treatment of cat allergen-induced asthma in children. J Allergy Clin Immunol, 109:794-9.
31. Pullerits T, Praks L, Ristioja V, et al. 2002. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol, 109:949-55.
32. Ratner PH, Howland WC, Arastu R, et al. 2003. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol, 109:536-42.
33. Ray NF, Baraniuk JN, Thamer M, et al. 1999. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunology, 103:401-7.
34. Singulair PI. 2005. Singulair prescribing information. Whitehouse Station, NJ: Merck & Co. Inc., June 1998-2005.
35. Togias A. 2000. Unique mechanistic features of allergic rhinitis. J Allergy Clin Immunol, 90:599-604.
36. Topuz B, Ogmen GG. 2003. Montelukast as an adjuvant to mainstay therapies in patients with seasonal allergic rhinitis. Clin Exp Allergy, 33:823-6.
37. van Adelsberg J, Philip G, LaForce CF, et al. 2003. Randomized controlled trial evaluating clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol, 90:214-22.
38. van Adelsberg J, Philip G, Pedinoff AJ, et al. 2003. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy, 58:1268-76.
39. van Cauwenberge P, Bachert C, Passalacqua G, et al. 2000. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy, 55:116-34.
40. Welsh PW, Stricker WE, Chu CP, et al. 1987. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc, 62:125-34.
41. White MV, Kaliner MA. 1992. Mediators of allergic rhinitis. J Allergy Clin Immunol, 90:699-704.
42. Wilson AM, Orr LC, Sims EJ, et al. 2001. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinits. Clin Exp Allergy, 31:61-8.
43. Wilson AM, Sims EJ, Orr LC, et al. 2001. Effects of topical corticosteroids and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol, 87:344-9.